CONTINUUS Awarded Phase IIB SBIR grant from NSF

CONTINUUS Pharmaceuticals was awarded a Phase IIB SBIR grant from the National Science Foundation to accelerate technical development and commercialization of its ICM technology platform. The grant consists of $500,000 over a two year extension period, which increases the total award of the Phase II project to $1,250,000.

Comments are closed.